Roivant Sciences Ltd. Common Shares (ROIV)
Stock · NASDAQ · Health Care
$33.53as of 10/16/2026
Price chart
Active signals
ROIV Signal Track Record
How signals performed across all stocks →What ROIV's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +3.8% | 69% | September 18, 2026 |
| Bollinger Band Breakout | 28 | +5.1% | 54% | September 8, 2026 |
| 200-Day Moving Average TouchActive now | 17 | +1.6% | 76% | August 11, 2025 |
| Bollinger Band Breakdown | 15 | +8.0% | 67% | July 29, 2026 |
| Any 20-session window (baseline) | +2.9% | 63% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated wit…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 721
- Website
- roivant.com/
Fundamentals
- 1-day range
- $34.15$35.59
- Market cap
- $25.38B
- P/E (trailing)
- —
- P/E (forward)
- -20.63
- EPS (trailing)
- $-0.39
- Dividend yield
- —
- Beta
- 1.19
- Avg. volume
- 7.03M
How Roivant Sciences Ltd. Common Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed May 20, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Roivant Sciences Ltd. Common Shares Competitors
Chosen by industry and closest market cap.
- ROIVRoivant Sciences Ltd. Common Shares$33.53▼ 1.50%Market cap $25.38BP/E —$15.9$42.5
- UTHRUnited Therapeutics Corporation Common Stock$533.12▼ 1.55%Market cap $22.62BP/E 17.78$409.07$609.35
- INSMInsmed Incorporated Common Stock$96.27▼ 2.96%Market cap $28.73BP/E —$90.39$212.75
- ALNYAlnylam Pharmaceuticals Inc. Common Stock$231.83▼ 0.94%Market cap $28.92BP/E 37.17$197.81$495.55
- VTRSViatris Inc. Common Stock$18.66▲ 2.41%Market cap $18.97BP/E —$9.73$18.43
- ZTSZoetis Inc. Class A Common Stock$79.38▲ 1.22%Market cap $32.39BP/E 12.43$68.77$148.3
- RPRXRoyalty Pharma plc Class A Ordinary Shares$60.96▲ 2.25%Market cap $32.97BP/E 41.57$35.23$64.38
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ROIV Roivant Sciences Ltd. Common Shares | $25.38B | — | $33.53 | ▼ 1.50% | $15.9$42.5 |
| UTHR United Therapeutics Corporation Common Stock | $22.62B | 17.78 | $533.12 | ▼ 1.55% | $409.07$609.35 |
| INSM Insmed Incorporated Common Stock | $28.73B | — | $96.27 | ▼ 2.96% | $90.39$212.75 |
| ALNY Alnylam Pharmaceuticals Inc. Common Stock | $28.92B | 37.17 | $231.83 | ▼ 0.94% | $197.81$495.55 |
| VTRS Viatris Inc. Common Stock | $18.97B | — | $18.66 | ▲ 2.41% | $9.73$18.43 |
| ZTS Zoetis Inc. Class A Common Stock | $32.39B | 12.43 | $79.38 | ▲ 1.22% | $68.77$148.3 |
| RPRX Royalty Pharma plc Class A Ordinary Shares | $32.97B | 41.57 | $60.96 | ▲ 2.25% | $35.23$64.38 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug ClassYahoo · 10/8/2026
- Transcript: Roivant Sciences Q1 2027 Earnings Conference CallBenzinga · 10/5/2026
- Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 YearsBenzinga · 10/1/2026
- Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 MonthsYahoo · 9/28/2026
- Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?Yahoo · 9/24/2026
- Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial MissYahoo · 9/23/2026
- Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus ErythematosusYahoo · 9/23/2026
- Immunovant Ends Autoimmune Skin Disorder ProgramBenzinga · 9/23/2026
Insider Activity
Insider Actions →- Epperly Melissa B, · October 1, 2026 · Option Exercise17.8K @ $4.46
- Epperly Melissa B, · October 1, 2026 · Sale900 @ $36.57
- Epperly Melissa B, · October 1, 2026 · Sale16.9K @ $36.08
- Mayukh Sukhatme · September 30, 2026 · Tax Withholding46.9K @ $36.57
- Eric Venker · September 30, 2026 · Option Exercise200.0K @ $3.85
- Eric Venker · September 30, 2026 · Sale200.0K @ $36.62
- Matthew Gline · September 30, 2026 · Tax Withholding76.2K @ $36.57
- Frank Torti · September 30, 2026 · Tax Withholding40.3K @ $36.57
- Richard Pulik · September 20, 2026 · Tax Withholding2.1K @ $39.77
- Jennifer Humes · September 20, 2026 · Tax Withholding3.9K @ $39.77
- Daniel Allen Gold · September 16, 2026 · Grant10.5K
- Daniel Allen Gold · September 16, 2026 · Grant5.1K
- Ilan Oren · September 16, 2026 · Grant10.5K
- Ilan Oren · September 16, 2026 · Grant5.1K
- Meghan Fitzgerald · September 16, 2026 · Grant10.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Roivant Sciences receives downgrades from Wolfe Research and analyst
Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.
Roivant Sciences receives downgrades from Wolfe Research and analyst. Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.